Advertisement

Helix Therapeutics LLC, a New Haven, Conn.-based biopharmaceutical company, has landed $2.5 million in new funding from venture firm Canaan Partners and the quasi-public state funding entity Connecticut Innovations.

According to Helix officials, the new funds will be used to move forward its proprietary targeted gene modification (TGM) technology platform, which the company says can correct certain genetic mutations in blood stem cells of patients with rare genetic diseases such as sickle cell anemia, B-Thalassemia and lysosomal storage disorders.

SOURCE

Advertisement
Advertisement